drugset / Trial / NCT04688983
Study in Adult Ph-positive ALL
RandomizedFactorialOpen-labelTreatment
Summary
An Open Label, 3-arm, Randomised Phase II Study to Compare the Safety and Efficacy of Ponatinib in Combination With Either Chemotherapy or Blinatumomab With Imatinib Plus Chemotherapy as Front-line Therapy for Patients Aged 55 Years and Over With Philadelphia Chromosome Positive (Ph+ or BCR-ABL+) Acute Lymphoblastic Leukemia (ALL)
Timeline
- Start
- 2021-01
- Primary completion
- 2024-01
- Completion
- 2026-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Blinatumomab | Monoclonal antibody | — | Intravenous |
| Comparator | Imatinib | Small molecule | 400 mg | Oral |
| Subject | Ponatinib | Small molecule | 30 mg | — |